ITI Life Sciences today announces it has committed £30 million as part of a new three-year R&D programme focused on the development of new near-patient and home use diagnostic tests. Initially, the programme will focus on developing near-patient tests based on novel biomarkers (indicators) for cardiovascular disease, which is a major cause of ill-health in Scotland, and where Scotland has acknowledged clinical expertise.
